CCLA Investment Management Sells 61,003 Shares of Zoetis Inc. $ZTS

CCLA Investment Management lessened its holdings in Zoetis Inc. (NYSE:ZTS) by 6.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 898,601 shares of the company’s stock after selling 61,003 shares during the period. Zoetis accounts for 2.1% of CCLA Investment Management’s holdings, making the stock its 26th biggest position. CCLA Investment Management owned about 0.20% of Zoetis worth $131,420,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its stake in shares of Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after buying an additional 2,978 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in Zoetis by 1,250.6% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 48,986 shares of the company’s stock valued at $8,066,000 after acquiring an additional 45,359 shares during the period. Compound Planning Inc. lifted its position in Zoetis by 9.0% during the first quarter. Compound Planning Inc. now owns 7,248 shares of the company’s stock worth $1,193,000 after acquiring an additional 597 shares during the last quarter. Sax Wealth Advisors LLC bought a new stake in shares of Zoetis during the first quarter worth approximately $646,000. Finally, Groupe la Francaise boosted its holdings in shares of Zoetis by 131.6% during the first quarter. Groupe la Francaise now owns 19,268 shares of the company’s stock worth $3,018,000 after acquiring an additional 10,947 shares during the period. 92.80% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ZTS. Argus reissued a “buy” rating and set a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Barclays began coverage on Zoetis in a report on Monday, December 8th. They set an “equal weight” rating and a $136.00 target price for the company. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. Bank of America lowered shares of Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 price target on the stock. in a research report on Monday, December 15th. Finally, UBS Group cut their price objective on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a report on Wednesday, November 5th. Six analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $160.18.

Zoetis Stock Down 0.3%

Shares of NYSE ZTS opened at $122.34 on Monday. The stock has a market capitalization of $53.91 billion, a P/E ratio of 20.60, a PEG ratio of 2.66 and a beta of 0.97. The stock’s fifty day moving average is $128.86 and its 200 day moving average is $144.31. Zoetis Inc. has a 52 week low of $115.25 and a 52 week high of $177.40. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same period in the prior year, the company posted $1.58 earnings per share. The business’s revenue for the quarter was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 1.7%. This is a positive change from Zoetis’s previous quarterly dividend of $0.50. The ex-dividend date of this dividend is Tuesday, January 20th. Zoetis’s payout ratio is 35.69%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.